3ZBF

Structure of Human ROS1 Kinase Domain in Complex with Crizotinib


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.282 
  • R-Value Work: 0.233 
  • R-Value Observed: 0.236 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Acquired Resistance to Crizotinib from a Mutation in Cd74-Ros1

Awad, M.M.Katayama, R.Mctigue, M.Liu, W.Deng, Y.Brooun, A.Friboulet, L.Huang, D.Falk, M.D.Timofeevski, S.Wilner, K.D.Lockerman, E.L.Khan, T.M.Mahmood, S.Gainor, J.F.Digumarthy, S.R.Stone, J.R.Mino-Kenudson, M.Christensen, J.G.Iafrate, J.Engelman, J.A.Shaw, A.T.

(2013) N Engl J Med 368: 2395

  • DOI: 10.1056/NEJMoa1215530
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently shown efficacy in the treatment of lung cancers with ROS1 translocations. Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a ...

    Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently shown efficacy in the treatment of lung cancers with ROS1 translocations. Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. We performed a biopsy of a resistant tumor and identified an acquired mutation leading to a glycine-to-arginine substitution at codon 2032 in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).


    Organizational Affiliation

    Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS
A
322Homo sapiensMutation(s): 0 
Gene Names: ROS1MCF3ROS
EC: 2.7.10.1
Find proteins for P08922 (Homo sapiens)
Go to UniProtKB:  P08922
NIH Common Fund Data Resources
PHAROS  P08922
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
VGH
Query on VGH

Download CCD File 
A
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
C21 H22 Cl2 F N5 O
KTEIFNKAUNYNJU-GFCCVEGCSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
VGHIC50:  199   nM  BindingDB
VGHKi:  2.0999999046325684   nM  Binding MOAD
VGHIC50 :  30   nM  PDBBind
VGHKd:  4.099999904632568   nM  BindingDB
VGHIC50:  6.5   nM  BindingDB
VGHIC50:  0.699999988079071   nM  BindingDB
VGHIC50:  60   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.282 
  • R-Value Work: 0.233 
  • R-Value Observed: 0.236 
  • Space Group: P 64
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 106.854α = 90
b = 106.854β = 90
c = 50.357γ = 120
Software Package:
Software NamePurpose
CNXrefinement
HKL-2000data reduction
SCALEPACKdata scaling
CNXphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-06-12
    Type: Initial release
  • Version 1.1: 2013-07-03
    Changes: Database references
  • Version 1.2: 2019-04-24
    Changes: Data collection, Other, Source and taxonomy
  • Version 1.3: 2019-05-08
    Changes: Data collection, Experimental preparation